Alaunos Therapeutics, Inc.
TCRT Healthcare Biotechnology
Alaunos Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $5,000.00, down 50.0% from fiscal 2024. In the quarter to June 2026, revenue grew 200.0%, EPS grew 34.9% and free cash flow grew 57.2%, each against the same quarter a year earlier.
Follow TCRT
Alaunos Therapeutics, Inc. (TCRT) Beneish M-score
Alaunos Therapeutics, Inc.'s Beneish M-score for fiscal 2025 is −4.88; values above −1.78 are the model's flag for possible earnings manipulation — a statistical screen, not a finding.
Beneish M-score, annual
Embed this chart
Annual newest first
| Period | Beneish M-score | Change (points) |
|---|---|---|
| FY2025 | −4.88 | (5.29) |
| FY2024 | 0.41 | (33.23) |
| FY2023 | 33.64 | 31.99 |
| FY2022 | 1.65 | (3,933.65) |
| FY2018 | 3935.29 | 3,929.45 |
| FY2017 | 5.85 | 13.17 |
| FY2016 | −7.33 | (3.09) |
| FY2015 | −4.24 | — |
How fiscal 2025’s score is made up
| Component | This year | Year before | Result | Points |
|---|---|---|---|---|
| Days’ sales in receivables index | 1.20 | — | 1.10 | |
| Gross margin index | 1.00 | — | 0.53 | |
| Asset quality index Asset quality not computable — index set to 1 | 1.00 | — | Set to 1 | 0.40 |
| Sales growth index | 0.50 | — | 0.45 | |
| Depreciation index Depreciation not reported — index set to 1 | 1.00 | — | Set to 1 | 0.12 |
| SG&A index | 1.29 | — | −0.22 | |
| Total accruals to total assets | (0.44) | — | −2.06 | |
| Leverage index | 1.09 | — | −0.36 | |
| Beneish M-score | Low — no pattern the model associates with manipulation | −4.88 | ||
How the Beneish M-score works
M = −4.84 + 0.920 × DSRI + 0.528 × GMI + 0.404 × AQI + 0.892 × SGI + 0.115 × DEPI − 0.172 × SGAI + 4.679 × TATA − 0.327 × LVGI (Beneish, 1999): eight changes in the accounts from one fiscal year to the next, which the model weighs for the pattern seen in companies that later restated their earnings. Higher is worse.
| below −2.22 | Low — no pattern the model associates with manipulation |
|---|---|
| −2.22 to −1.78 | Elevated |
| above −1.78 | Flagged by the model |
−1.78 is the cut-off usually quoted from the paper, −2.22 a common conservative one. A statistical screen, not a finding of wrongdoing.
When asset quality, depreciation or SG&A cannot be worked out, that index is set to 1, as Beneish did, and the breakdown says so; with all three missing there is no score. Depreciation includes amortisation, and asset quality leaves out securities. Not worked out for banks, insurers and REITs.
Beneish M-score against peers
| Company | Beneish M-score |
|---|---|
| TCRT Alaunos Therapeutics, Inc. | −4.9× |
| ENVB Enveric Biosciences, Inc. compare | −4.7× |
| LEXX Lexaria Bioscience Corp. compare | −3.6× |
| TRAW Traws Pharma, Inc. compare | 2,517× |
| SYBX Synlogic, Inc. compare | — |
| EVGN Evogene Ltd. compare | — |
| FBLG FibroBiologics Inc. compare | — |
| ALZN Alzamend Neuro, Inc. compare | — |
| ACXP Acurx Pharmaceuticals, Inc. compare | — |
What Beneish M-score is
The Beneish M-Score combines eight year-on-year changes in the accounts into a statistical screen for patterns seen in companies that overstated earnings.
−4.84 + 0.920 × DSRI + 0.528 × GMI + 0.404 × AQI + 0.892 × SGI + 0.115 × DEPI − 0.172 × SGAI + 4.679 × TATA − 0.327 × LVGI